Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis, Alcon, Xediton Pharma - LARVOL DELTA

Multimodal imaging application of Sturge-Weber syndrome complicated with glaucoma: a case report of non-surgical treatment in a 7-year-old boy. (PubMed, BMC Ophthalmol) - "In selected pediatric SWS patients with refractory glaucoma, bimatoprost may achieve excellent IOP control, avoiding surgical risks. Multimodal imaging is essential for accurate diagnosis and monitoring. This case challenges the traditional view that topical medications are ineffective in SWS-related glaucoma and highlights the potential of prostaglandin analogs as a first-line or early adjunctive therapy."

Journal • Glaucoma • Ophthalmology • Pediatrics • Retinal Disorders

Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data. (PubMed, Ophthalmol Ther) - "These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Post-Marketing Surveillance Reveals Amplified Adverse Event Burden Across Topical Pharmacotherapies for Primary Open-Angle Glaucoma (ARVO 2026) - "The FDA-approved drugs evaluated included bimatoprost, tafluprost, travoprost, latanoprost, omidenepag, timolol, brimonidine, brinzolamide, dorzolamide, netarsudil, brinzolamide-brimonidine, and brimonidine-timolol. With average trial lengths of 15 months versus chronic real-world use, post-marketing data reveal multisystem and mortality-associated safety signals not detected pre-approval. These findings highlight gaps in the POAG trial safety reporting and may support the need for extended pharmacovigilance beyond formal trial periods."

Adverse events • P4 data • Glaucoma • Ophthalmology

Effects of Ripasudil Hydrochloride Hydrate-Brimonidine Tartrate Fixed-Dose Combination Using Rho Kinase Inhibitor and Alpha2 Adrenergic Receptor Agonist on Aqueous Column in the Episcleral Vein: A Randomized, Double-Masked, Crossover Clinical Trial (ROCK Alpha-Aqua Study). (PubMed, J Clin Med) - " This single-center randomized clinical trial included healthy adult volunteers who received GLAALPHA, a brimonidine tartrate-brinzolamide fixed-dose combination (Ailamide), or brimonidine tartrate monotherapy (Aiphagan) in a crossover sequence. In healthy adult eyes, GLAALPHA significantly increased the aqueous column width in the episcleral veins 2 h after instillation, indicating enhanced conventional aqueous outflow. These findings provide evidence that GLAALPHA promotes trabecular outflow beyond the effects of brimonidine tartrate-containing comparators and offer mechanistic insights into its action."

Clinical • Journal

Pharmacologic Interaction in an Elderly Patient with Kidney Dysfunction: Acetazolamide and Aspirin in Focus (KIDNEY WEEK 2025) - "He was managed with brimonidine, brinzolamide, timolol, and oral acetazolamide 250 mg twice daily, and was discharged. He was concurrently on aspirin (81mg), furosemide, empagliflozin, atorvastatin, and sertraline...Although rare, there is no warning sign on EMR for these medications to commence in CKD patients concurrently. Recognizing such interactions is critical to improving medication safety in older adults with CKD."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Geriatric Disorders • Glaucoma • Metabolic Disorders • Mood Disorders • Nephrology • Ophthalmology • Psychiatry • Renal Disease

TB or not TB: what's the verdict? (SOE 2025) - "Patient was shifted from brimonidine to brinzolamide and started on low dose topical 0.2% Loteprednol due to fear of steroid induced rise in IOP... Drug induced uveitis is a rare entity; however, treating ophthalmologists should have a high suspicion of it in patients receiving brimonidine for glaucoma. Timely diagnosis and cessation of drug can prevent unwanted investigations and long term steroid treatment."

Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Periorbital skin hypopigmentation associated with the use of topical glaucoma medications. (PubMed, Digit J Ophthalmol) - "Timolol and brinzolamide/brimonidine have not been associated with changes in skin pigmentation in the ophthalmic literature. Our case most likely represents a rare instance of paradoxical skin depigmentation associated with latanoprost use and adds to the limited literature on this clinical entity."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Changes in ocular higher-order aberrations and corneal backward light scattering after instillation of brimonidine/brinzolamide versus brimonidine/timolol: a randomized, double-masked, crossover clinical trial (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center

New P4 trial • Glaucoma • Ophthalmology

Comparison of the Effects of Timolol, Brinzolamide, Brimonidine and Netarsudil in a Rabbit Model of Water Loading-Induced Ocular Hypertension. (PubMed, Curr Eye Res) - "These results could provide data for characterizing each medication. These data may aid in the development of new glaucoma medications through the combination of existing medications."

Journal • Preclinical • Cardiovascular • Glaucoma • Ophthalmology

Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. (PubMed, Ophthalmol Ther) - "Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion."

Clinical • Journal • Allergy • Glaucoma • Immunology • Ophthalmology • Retinal Disorders

Comparative Effects of GLP-1 Receptor Agonists and Metformin on Glaucoma Risk in Type 2 Diabetes Patients. (PubMed, Ophthalmology) - "GLP-1 receptor agonists are associated with a significantly lower incidence of POAG, ocular hypertension, and the need for first-line glaucoma treatments compared to metformin in patients with type 2 diabetes. These findings highlight the potential ocular benefits of GLP-1 receptor agonists and their expanding role in the clinical management of diabetic patients."

Journal • Cardiovascular • Diabetes • Glaucoma • Metabolic Disorders • Ophthalmology • Type 2 Diabetes Mellitus

Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination. (PubMed, Jpn J Ophthalmol) - "Our findings reveal that compared with the concomitant use of BZM and BMD, BBFC is effective in reducing corneal epithelial damage."

Journal • Glaucoma • Keratitis • Ocular Inflammation • Ophthalmology

Comparison of allergy prevalence using brinzolamide 1.0% / brimonidine 0.2% fixed combination with and without β-blocker in glaucoma patients: a retrospective cohort study. (PubMed, BMC Ophthalmol) - "Concurrent use of β-blocker with BBFC decreases allergy prevalence, delays allergy onset, and predominantly results in follicular conjunctivitis, thereby facilitating longer treatment duration. Understanding these characteristics of allergy in BBFC users is useful to manage patients and improve treatment adherence. This study provides insights into the role of β-blockers in modulating ocular allergy in BBFC-treated glaucoma patients, highlighting implications for clinical practice and patient education."

Clinical • Journal • Retrospective data • Allergy • Conjunctivitis • Glaucoma • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

A Simple Validated LC-UV Method for the Simultaneous Determination of Brimonidine and Brinzolamide in the Presence of Brinzolamide's Degradation Product (Major Metabolite) in Rabbit Aqueous Humor. (PubMed, J Chromatogr Sci) - "Dorzolamide hydrochloride (DZ) was used as an internal standard (IS). The method was confirmed to be accurate, precise and linear over a range of 100.0-1000.0 ng mL-1 for BM and BZ. The method developed herein is simple, safe, eco-friendly, rapid and accurately applied for the quantification of BM and BZ, along with the successful separation of NDBZ, which is considered as a potential irritant degradation product of BZ."

Journal • Preclinical

A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension. (PubMed, J Ocul Pharmacol Ther) - " Although LT showed slightly better and sustained IOP reduction, the difference was not statistically significant. Both BB and LT demonstrated comparable outcomes for managing POAG and OHT."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals. (PubMed, J Curr Glaucoma Pract) - "Brimonidine and brinzolamide (14.17%) was the most prescribed combination in group II, while Brimonidine with Timolol (7.87%) in group I. In group I, Timolol and Travoprost were the most prescribed medications for both PACD and POAG...Bhartiya S, Ichhpujani P, Parmar UPS, et al.Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals. J Curr Glaucoma Pract 2024;18(1):16-22."

Journal • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

The effect of a brinzolamide/brimonidine fixed combination on optic nerve head blood flow in rabbits. (PubMed, PLoS One) - "BBFC effectively reduces IOP and mitigates diurnal fluctuation-induced decreases in ONH BF."

Journal • Preclinical

The First Study on Fixed-Dose Combination of Timolol + Brimonidine + Brinzolamide Eye Drops for OAG/Ocular Hypertension (AAO 2023) - "Conclusion Our study establishes that triple FDC is safe, effective and well tolerated. Triple FDC can be an effective option in glaucoma management."

Glaucoma • Ophthalmology

Patient Factors Influencing Intraocular Penetration of Brimonidine-Related Eye Drops in Adults: A Post Hoc Pooled Analysis. (PubMed, Ophthalmol Ther) - "The findings of this study emphasize the necessity of considering individual differences in ocular pharmacokinetics during drug therapy (formulation design of the eye drops and dose regimen)."

Journal • Retrospective data • Ophthalmology

Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients. (PubMed, Jpn J Ophthalmol) - "BBFC can be used concomitantly with PG or PG/beta FC to reduce IOP without serious complications."

Clinical • Journal • Cardiovascular • Glaucoma • Ophthalmology

Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study. (PubMed, J Clin Med) - "Sufficient concentrations of brimonidine were detected in all vitreous samples. The dissociated correlation of the drug concentrations between aqueous and vitreous humors implies the possibility of another pathway to vitreous humor, different from the pathway to aqueous humor."

Journal • Ophthalmology • Retinal Disorders

Effect of patient factors on ocular pharmacokinetics in ophthalmic drug administration (ARVO 2023) - "The subjects were 42 patients who were scheduled for vitrectomy and received brimonidine related eye drops (0.1% brimonidine tartrate ophthalmic solution, 0.1% brimonidine tartrate and 0.68% timolol maleate fixed-combination ophthalmic solution or 0.1% brimonidine tartrate and 1% brinzolamide fixed-combination suspension) twice daily for 1 week...Describe the big picture and the implications of your findings, not the study itself and the associated details. We evaluated effect of patient factors on ocular pharmacokinetics in order to achieve the formulation design of eye drops and the drug therapy in consideration of individual differences."

Clinical • PK/PD data • Ophthalmology